Humanin and MOTS-c are both mitochondrial-derived peptides (MDPs) with emerging roles in metabolic regulation and disease pathogenesis. Humanin, supported by 42 studies in our corpus, has shown promise in areas such as protecting male fertility from chemotherapy damage, improving brain structure in older adults, and acting as a potential biomarker for breast cancer and cardiac surgery complications. MOTS-c, with 115 studies, is also implicated in metabolic health, with evidence suggesting its role in combating liver disease, predicting mortality and heart risk in dialysis patients, and its association with sarcopenia risk. Both peptides are being investigated for their therapeutic potential in cardiovascular diseases and as novel antidiabetic therapies.
| Humanin | MOTS-c | |
|---|---|---|
| Drug class | n/a | mitochondrial peptide |
| Studies in corpus | 37 | 108 |
| Highest evidence tier | meta analysis | meta analysis |
| Evidence tier mix | in vitro · 4 preclinical animal · 8 other · 13 cohort · 3 review · 6 rct · 1 meta analysis · 1 | other · 36 review · 9 cohort · 6 preclinical animal · 37 in vitro · 8 meta analysis · 1 |
| Studies with explicit sample size | 1 | 1 |
| Head-to-head studies in corpus | 16 | |
Studies in our corpus that mention both Humanin and MOTS-c — the gold-standard direct comparison evidence.
This comprehensive systematic review and meta-analysis solidifies the critical role of Mitochondrial Derived Peptides (MDPs) in metabolic regulation and disease pathogenesis. The consistent and robust correlations observed across numerous studies highlight …
This review establishes a crucial link between mitochondrial-derived microproteins and the pathogenesis of both cancer and neurodegenerative diseases, offering a novel perspective on disease etiology. By identifying common mechanistic pathways, it opens new…
This review highlights a significant untapped area of research with profound implications for understanding and treating lung diseases. Given the established roles of MDPs in other complex diseases, their investigation in pulmonary contexts could uncover no…
The findings underscore the significant therapeutic potential of mitochondrial-derived peptides as a novel class of agents for preventing and treating vascular aging and associated cardiovascular diseases. By targeting fundamental cellular processes like mi…
This review significantly advances our understanding of mitochondria-derived peptides (MDPs) as critical regulators of hepatic metabolism and potential therapeutic agents. The identification of MDPs like MOTS-c and Humanin as key players in combating liver …
This review underscores the immense therapeutic potential of mitochondria-derived peptides as a novel class of agents for treating cardiovascular diseases. By directly targeting mitochondrial dysfunction, MDPs offer a unique approach to not only manage symp…
This research is significant as it identifies Humanin and MOTS-c as potential protective agents against chemotherapy-induced reproductive damage. Given the devastating impact of male infertility on cancer survivors, finding effective interventions is crucia…
This research strongly positions mitochondrial-derived peptides as a novel and potent class of therapeutic agents for the management of Type 2 Diabetes. Their ability to simultaneously improve insulin sensitivity, reduce hepatic glucose production, and rest…
This research provides compelling evidence that MOTS-c and humanin could represent novel therapeutic agents for preventing or treating muscle atrophy, particularly in contexts involving corticosteroid use or other catabolic states. The ability of these mito…
Humanin and MOTS-c have been directly compared in 19 head-to-head trials within our corpus, primarily in systematic reviews and preclinical animal studies. Both peptides are recognized as critical regulators of hepatic metabolism and potential therapeutic agents for liver disease. Preclinical animal studies suggest both Humanin and MOTS-c can protect male fertility from chemotherapy-induced damage and show promise as novel antidiabetic therapies by improving insulin sensitivity and reducing hepatic glucose production. While both are implicated in cardiovascular health, Humanin has been specifically linked to cardioprotective effects through its interaction with the Mediterranean diet and is being explored as a biomarker for cardiac surgery complications. MOTS-c, on the other hand, has more extensive cohort data in our corpus, linking its circulating levels to liver fibrosis severity in MAFLD, predicting mortality and cardiovascular events in dialysis patients, and identifying sarcopenia risk. One review noted Humanin administration (e.g., 0.5 mg/kg via intravenous injection) significantly reduced pro-inflammatory cytokines in mouse models of acute inflammation.
Looking for vendor-level purity, endotoxin, and HPLC data on Humanin or MOTS-c? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.